Asset Management One Co. Ltd. lifted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 0.8% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 365,070 shares of the medical instruments supplier’s stock after buying an additional 3,073 shares during the period. Asset Management One Co. Ltd. owned approximately 0.16% of Becton, Dickinson and worth $71,494,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in BDX. Family Firm Inc. lifted its stake in Becton, Dickinson and by 0.5% in the second quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock valued at $236,000 after purchasing an additional 6 shares during the last quarter. Northwest Quadrant Wealth Management LLC lifted its stake in Becton, Dickinson and by 0.4% in the second quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock valued at $332,000 after purchasing an additional 6 shares during the last quarter. Wellington Shields & Co. LLC lifted its stake in Becton, Dickinson and by 0.3% in the second quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock valued at $496,000 after purchasing an additional 7 shares during the last quarter. Northstar Group Inc. lifted its stake in Becton, Dickinson and by 0.3% in the second quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock valued at $584,000 after purchasing an additional 9 shares during the last quarter. Finally, NBT Bank N A NY lifted its stake in Becton, Dickinson and by 0.3% in the second quarter. NBT Bank N A NY now owns 3,351 shares of the medical instruments supplier’s stock valued at $654,000 after purchasing an additional 10 shares during the last quarter. Hedge funds and other institutional investors own 88.46% of the company’s stock.

Several equities analysts recently commented on the company. Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 price objective on shares of Becton, Dickinson and in a research note on Friday, November 3rd. Royal Bank Of Canada reissued a “sector perform” rating and set a $230.00 target price (up previously from $210.00) on shares of Becton, Dickinson and in a report on Friday, November 3rd. Morgan Stanley boosted their target price on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Wells Fargo & Company reissued a “positive” rating and set a $235.00 target price (up previously from $225.00) on shares of Becton, Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. Finally, Zacks Investment Research raised shares of Becton, Dickinson and from a “sell” rating to a “hold” rating in a report on Friday, October 20th. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $217.08.

Becton, Dickinson and Company (NYSE:BDX) opened at $218.92 on Thursday. The firm has a market cap of $49,943.21, a price-to-earnings ratio of 23.08, a PEG ratio of 1.72 and a beta of 1.07. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $229.68. The company has a debt-to-equity ratio of 1.44, a current ratio of 5.58 and a quick ratio of 5.03.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the consensus estimate of $2.37 by $0.03. The firm had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The business’s quarterly revenue was down 2.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.12 earnings per share. research analysts expect that Becton, Dickinson and Company will post 10.63 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be issued a $0.75 dividend. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $3.00 annualized dividend and a dividend yield of 1.37%. This is a boost from Becton, Dickinson and’s previous quarterly dividend of $0.73. Becton, Dickinson and’s dividend payout ratio is presently 62.80%.

In related news, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the transaction, the insider now owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Stephen Sichak sold 11,787 shares of the stock in a transaction on Friday, September 8th. The shares were sold at an average price of $200.46, for a total value of $2,362,822.02. Following the completion of the transaction, the insider now directly owns 14,038 shares in the company, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/07/becton-dickinson-and-company-bdx-shares-bought-by-asset-management-one-co-ltd.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.